04-28-2026Price:

The Frontier

Your signal. Your price.

SCIENCE

Sinclair launches human age-reversal trials

Tuesday, April 28, 2026 · from 1 podcast
1 SOURCEMoonshots with Peter Diam…
  • David Sinclair begins first human trials using OSK genes to reverse cellular aging, starting with vision loss.
  • Aiming for a cheap, pill-based alternative to million-dollar gene therapies.
  • Private funding via 'Friends of Sinclair Lab' bypasses slow academic systems.

David Sinclair has crossed the threshold from theory to human testing. His lab is now enrolling patients in the first clinical trials of epigenetic reprogramming using three Yamanaka genes - OSK - to reverse cellular age in humans, starting with glaucoma-induced blindness. This isn't slowing aging. It’s attempting to turn back the clock.

Six weeks after political friction nearly ended his funding, Sinclair confirmed on Moonshots with Peter Diamandis that the trials are imminent. In animals, OSK restored vision by resetting optic nerve cells to a younger state. If it works in humans, it proves aging isn’t a one-way street. The same reprogramming has already reversed age in mouse brains, kidneys, and muscles.

"We’re not just slowing aging - we’re reversing it at the cellular level."

- David Sinclair, Moonshots with Peter Diamandis

The real barrier isn’t science - it’s delivery. Current gene therapies cost up to $2 million per dose. Sinclair’s team is using AI to screen billions of molecules for a small-molecule substitute: a daily pill that mimics OSK. He expects a candidate to enter human trials within months, targeting a metformin-level price - pennies per dose.

The push is being funded outside traditional channels. After losing $1-3 million in annual NIH grants, Sinclair and Diamandis launched 'Friends of Sinclair Lab' (FOSL), raising $6 million from 70 private backers. The model skips bureaucratic delays: from idea to experiment in weeks, not years. One recent project reversed kidney failure in a lab member - fast-tracked because the need was urgent.

"The FOSL model is real-time science. We fund what we believe in, and we move."

- Peter Diamandis, Moonshots with Peter Diamandis

Sinclair believes 2026 could be the year human age reversal is proven possible. His goal: reach 'longevity escape velocity' - where each year of life gained adds more than a year of healthy extension. The era of waiting for institutions is over.

LongevityBiologyHealth
Peter DiamandisMetformin

Source Intelligence

- Deep dive into what was said in the episodes

Moonshots with Peter Diamandis
Moonshots with Peter Diamandis

David Sinclair on the Longevity Pill, Age Reversal Timelines, and Updated Protocols | EP #250 • Apr 27

  • David Sinclair's lab is days away from the first human epigenetic reprogramming trial, using a subset of three Yamanaka genes (OSK) in the eye of a patient to cure blindness, following successful mouse and monkey trials.
  • The epigenetic reprogramming technology shows benefits across various tissues in mice, including brain age reversal, memory improvement, and positive effects on motor neurons (ALS models), immune system, muscle, kidney, liver, skin, and joints.
  • Current human trials for targeted gene therapies, using adeno-associated viruses (AAV) for OSK delivery, typically cost between $500,000 and $2 million per treatment, but Sinclair aims for widespread, affordable application.
  • The Sinclair Lab developed a small molecule cocktail using AI screening, achieving proof of concept in reversing skin cells from 92-year-olds to a 20-year-old state. This cocktail aims for human clinical trials within months, with potential costs of a few cents per pill at scale.
  • David Sinclair believes there is no biological or physical law limiting human lifespan, suggesting it's possible to live hundreds or thousands of years by repeatedly resetting cells, akin to how the Wright Brothers’ flight opened possibilities beyond early expectations.
  • Peter Diamandis initiated the 'Friends of Sinclair Lab' (FOSL) to provide private, direct funding to David Sinclair's research after his government grants, totaling $1-3 million annually, were cut. FOSL has since raised approximately $6 million in annual support from around 70 members.
  • Sinclair projects that age reversal in humans could be definitively proven as possible as early as 2026, marking a pivotal moment in longevity research.
  • David Sinclair's personal longevity protocol includes resveratrol (taken with oil for absorption), NMN, and glucose-lowering medications like metformin (1 gram daily) or berberine. He also takes nattokinase (10,000 units daily), which has shown to reverse arterial plaque.
  • Sinclair emphasizes dietary adjustments like a mostly vegan diet, avoiding processed carbohydrates, and significantly reducing alcohol consumption due to new data linking even one daily glass to smaller brain size. He monitors health with carotid ultrasounds, preferring them over radiation-emitting CT scans.
  • Maintaining social connections, reducing stress through practices like meditation, and ensuring adequate sleep are crucial for longevity, as loneliness and chronic tension accelerate aging and negatively impact biomarkers like blood pressure and cholesterol.
LongevityBiologyHealthStartups